Companies › Sichuan Clover Biopharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 1; Hematology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SCB-219M TNF receptor II-Fc fusion protein with TPO mimetic peptide | TNFRSF1B, THPO | Phase 1 | Chemotherapy-induced Thrombocytopenia (CIT) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05426369 | SCB-219M | Phase 1 | Chemotherapy-induced Thrombocytopenia (CIT) | Hematology | Jul 2025 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.